Introduction
Surgery remains the most effective and the only curative treatment for the majority of cancer patients with solid tumors. The earliest accounts of surgical treatment of tumors are found in the Papyrus dating back to 1600 BC [1] . In the modern era, McDowell performed the first elective abdominal tumor resection of a 22-lb ovarian mass in 1809. However, it was not until the mid-19th century, with the use of anesthesia (Warren 1846) and the introduction of antisepsis (Lister 1867) , that elective surgical techniques for the treatment of cancer became much more acceptable. Rapid developments in the field by Billroth (esophagectomy, 1872; laryngectomy, 1873; gastrectomy, 1881) , Kocher (thyroidectomy, 1876), Halsted (radical mastectomy, 1890) and others soon followed [2] .
Surgical oncology has evolved from being the only treatment modality for cancer patients to being one component, albeit an essential one, in the multimodality approach to the management of patients with solid tumors. The role of the surgical oncologist now encompasses all areas of cancer care, including prevention, diagnosis, staging, treatment, and palliation.
Prevention
The surgical oncologist should be aware of all conditions that carry an increased risk for developing a malignancy, in order to intervene earlier in the natural history of malignant transformation. A subset of these conditions may benefit from prophylactic surgical intervention to prevent the progression of their disease to an invasive cancer.
The cases of familial adenomatous polyposis coli (FAP) syndrome and hereditary nonpolyposis colorectal cancer (HNPCC) are prime examples. Prophylactic colectomy or proctocolectomy is indicated in these patients who are at very high risk of developing colon cancer [3, 4] . A review of the outcome of colectomy and ileorectal anastomosis in these patients shows a relatively low complication rate and acceptable functional outcome for a prophylactic procedure [4] .
Ulcerative colitis (UC) is another disease that carries an increased risk of developing colon cancer, estimated at 1% per year starting years after initial diagnosis. Patients with UC require surveillance colonoscopies and prophylactic proctocolectomy if dysplasia is detected on biopsy [5] .
Another example where prophylactic surgery may be indicated is in patients with multiple endocrine neoplasia (MEN) II syndrome. These patients carry germline mutations in the RET protooncogene, and are affected by medullary thyroid carcinoma (MTC), pheochromocytoma, parathyroid hyperplasia (MEN IIA) and mucosal neuromas (MEN IIB), where the course of the thyroid lesion essentially determines the prognosis and outcome. MTC develops in virtually all patients with MEN II and is the only component of the syndrome that is invariably malignant. Hence, it is recommended that patients with these disease-specific mutations undergo prophylactic total thyroidectomy at as early as 5 years of age [6, 7] .
Barrett's esophagus represents metaplastic change of the mucosal lining of the esophagus from normal squamous to columnar epithelium, occurring in 5%-10% of patients with chronic gastroesophageal reflux disease. Patients with Barrett's esophagus require continuous endoscopic surveillance at regular intervals to screen for dysplasia.
Approximately 50% of patients with high-grade dysplasia will have adenocarcinoma on pathological examination and a large percentage of the remaining patients will go on to develop neoplasia. Although controversial, the presence of high-grade dysplasia in the setting of Barrett's esophagus is considered an indication for esophageal resection [8] . Photodynamic ablation therapy is being evaluated as an alternative to esophagectomy in the treatment of Barrett's esophagus. Preliminary data suggests that it may provide safe and effective ablation of dysplastic epithelium [9, 10] .
The discovery of BRCA1/2 genes has fueled a controversy regarding prophylactic mastectomy, which can provide at least a 90% reduction in the risk of breast cancer. Patients carrying germline mutations of BRCA1/2 have an estimated 87% risk of developing breast cancer and a 44% risk of developing ovarian cancer by age 70. Patients and family members with these mutations require close surveillance (mammography and pelvic ultrasound) in addition to genetic counseling [11, 12] . The role of surgical prophylaxis is as yet undefined, but may be an appropriate option in select, properly informed groups of patients.
Diagnosis and Staging
Accurate diagnosis and staging is imperative in directing the course of cancer patient management and the essential step of obtaining tissue for histopathological examination frequently falls into the surgeon's domain. With the advent of more sophisticated techniques of tissue analysis (e.g., immunohistochemistry, flow cytometry, hormone receptor analysis, molecular markers, mutational analysis, etc.), this process has become increasingly important. The spectrum of procedures used for tissue acquisition includes fine needle aspiration (FNA), core needle biopsy (CNB), incisional biopsy, and excisional biopsy.
An FNA may be sufficient to diagnose or rule out a malignant process by cytological analysis in the parotid gland, thyroid gland, breast, or lymph node. Stereotactic CNB has been utilized for evaluating suspicious breast lesions and has comparable, if not superior sensitivity and specificity and lower suspicious readings when compared to FNA [13, 14] . CNB has been shown to provide equivalent data (grade, tumor type), with less morbidity, and has supplanted incisional biopsy in most instances [15, 16] . Incisional biopsy entails removal of a small segment of tissue from the tumor, and along with CNB, is the preferred method for diagnosing tumor masses such as extremity sarcomas, where extensive dissection for biopsy purposes may compromise subsequent curative resection [17, 18] . Excisional biopsy consists of resecting all gross visible tumor and is recommended for small tumor masses and enlarged lymph nodes. Care should be taken to choose the appropriate method of tissue sampling for a given clinical situation.
With the advent of laparoscopy in the 1980s, cancer staging has been revolutionized in a number of solid tumor types. The combination of diagnostic laparoscopy and laparoscopic ultrasonography has been shown to be consistently superior to other preoperative imaging modalities in the staging of abdominal malignancy [19] . Consequently there has been an improvement in the management of these patients, demonstrated by reductions in nontherapeutic laparotomies, improved resectability rates, and optimization of palliation with less associated morbidity [20] . The applications of laparoscopy for staging are multiple. One example is the use of laparoscopy in the management of patients with peripancreatic carcinoma. Prior to the routine use of laparoscopy, the majority of patients would undergo obligate celiotomy and only a very small proportion would be deemed resectable for cure. The use of laparoscopy as an initial staging tool has allowed many patients to avoid unnecessary laparotomy with its attendant morbidity. If, at the time of laparoscopy, any liver metastases, omental or peritoneal implants are found, resection is contraindicated. Locally advanced tumors that encase the portal vein, mesenteric vessels or the celiac axis can be identified with the use of laparoscopic ultrasound. Finally, palliative bypass procedures can be performed via minimally invasive approaches and spare the patient a laparotomy [21, 22] . Laparoscopy has been used in a similar fashion for the management of patients with gastric carcinoma. Patients found to have peritoneal tumor implants, liver metastases,
